Modafinil doesn't improve NSCLC-related fatigue

April 30, 2014
Modafinil doesn't improve NSCLC-related fatigue

(HealthDay)—The central nervous system stimulant modafinil is not effective in treating non-small-cell lung cancer-related fatigue, according to a study published online April 28 in the Journal of Clinical Oncology.

Anna Spathis, M.B., B.Chir.,from Cambridge University Hospitals National Health Service Foundation Trust in the United Kingdom, and colleagues randomly assigned adults with advanced non-small-cell lung cancer, who were not treated with chemotherapy or radiotherapy within the last four weeks, to receive either daily (75 patients) or matched placebo (85 patients). Questionnaires were completed at baseline and day 28.

The researchers found that, from baseline to day 28, Functional Assessment of Chronic Illness Therapy-Fatigue scores improved in both groups (mean score change: modafinil, 5.29; placebo, 5.09), with no difference between treatment groups (mean score change difference: 0.20; 95 percent confidence interval, −3.56 to 3.97). Secondary outcomes of patient-reported measures of depression, daytime sleepiness, and quality of life were not different between treatment groups. Forty-seven and 23 percent of the modafinil and placebo groups, respectively, stated that the intervention was not helpful.

"Modafinil had no effect on cancer-related fatigue and should not be prescribed outside a clinical trial setting," the authors write. "Its use was associated with a clinically significant placebo effect."

Matched modafinil and capsules were provided by Bilcare Global Clinical Supplies Europe.

Explore further: L-carnitine does not reduce cancer-related fatigue

More information: Abstract
Full Text

Related Stories

L-carnitine does not reduce cancer-related fatigue

September 18, 2012

(HealthDay)—Patients with invasive malignancies who take L-carnitine supplements do not experience a reduction in fatigue, pain, or depression, according to research published online Sept. 17 in the Journal of Clinical ...

Dexamethasone beats placebo for cancer-related fatigue

August 1, 2013

(HealthDay)—For patients with advanced cancer, dexamethasone is better than placebo for reducing cancer-related fatigue (CRF), according to a study published online July 29 in the Journal of Clinical Oncology.

Recommended for you

Combination therapy can prevent cytostatic resistance

November 26, 2015

Researchers at Karolinska Institutet have found a new way of preventing resistance to cytostatics used in the treatment of cancers such as medulloblastoma, the most common form of malignant brain tumour in children. The promising ...

Forecasting the path of breast cancer in a patient

November 23, 2015

USC researchers have developed a mathematical model to forecast metastatic breast cancer survival rates using techniques usually reserved for weather prediction, financial forecasting and surfing the Web.


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.